Explaining fatigue in ANCA-associated vasculitis

Explaining fatigue in ANCA-associated vasculitis

Pokaži ostale verzije (1)

Bibliografski detalji
Glavni autori:	Basu, N, McClean, A, Harper, L, Amft, E, Dhaun, N, Luqmani, R, Little, M, Jayne, D, Flossmann, O, McLaren, J, Kumar, V, Erwig, L, Reid, D, Macfarlane, G, Jones, G
Format:	Journal article
Izdano:	2013

Slični predmeti

Explaining fatigue in ANCA-associated vasculitis.
od: Basu, N, i dr.
Izdano: (2013)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
od: Basu, N, i dr.
Izdano: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis
od: Basu, N, i dr.
Izdano: (2014)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
od: Basu, N, i dr.
Izdano: (2014)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
od: Basu, N, i dr.
Izdano: (2012)

Markers for work disability in ANCA-associated vasculitis
od: Basu, N, i dr.
Izdano: (2013)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
od: Basu, N, i dr.
Izdano: (2014)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
od: Salisbury, E, i dr.
Izdano: (2003)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
od: Salisbury, E, i dr.
Izdano: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
od: Salisbury, E, i dr.
Izdano: (2004)

Cardiovascular outcomes in ANCA associated vasculitis
od: Mukhtyar, C, i dr.
Izdano: (2008)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
od: Salisbury, E, i dr.
Izdano: (2003)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
od: McLaren, J, i dr.
Izdano: (2003)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
od: Suppiah, R, i dr.
Izdano: (2011)

Long-term survival of ANCA-associated vasculitis
od: Flossmann, O, i dr.
Izdano: (2009)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
od: Luqmani, R, i dr.
Izdano: (2007)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
od: McLaren, J, i dr.
Izdano: (2004)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
od: McLaren, J, i dr.
Izdano: (2001)

Long-term patient survival in ANCA-associated vasculitis
od: Flossmann, O, i dr.
Izdano: (2011)

Long-term patient survival in ANCA-associated vasculitis.
od: Flossmann, O, i dr.
Izdano: (2011)

Diagnosis and management of ANCA associated vasculitis.
od: Berden, A, i dr.
Izdano: (2012)

Long-term patient survival in ANCA-associated vasculitis.
od: Flossmann, O, i dr.
Izdano: (2011)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
od: McLaren, J, i dr.
Izdano: (2000)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
od: Robson, J, i dr.
Izdano: (2013)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
od: Robson, J, i dr.
Izdano: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
od: Robson, J, i dr.
Izdano: (2015)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
od: Lapraik, C, i dr.
Izdano: (2007)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
od: Ntatsaki, E, i dr.
Izdano: (2014)

Predictors of renal involvement in ANCA associated vasculitis
od: Kronbichler, A, i dr.
Izdano: (2018)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
od: Suppiah, R, i dr.
Izdano: (2011)

Damage assessment in ANCA-associated vasculitis.
od: Bhamra, K, i dr.
Izdano: (2012)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
od: Suppiah, R, i dr.
Izdano: (2011)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
od: Robson, J, i dr.
Izdano: (2013)

Maintenance of clinical remission in ANCA-associated vasculitis.
od: Luqmani, R
Izdano: (2013)

Outcome measures in ANCA-associated vasculitis.
od: Suppiah, R, i dr.
Izdano: (2010)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
od: Luqmani, R, i dr.
Izdano: (2017)

Comparison of disease activity measures for ANCA-associated vasculitis.
od: Merkel, P, i dr.
Izdano: (2004)

Diagnosis and assessment of systemic vasculitis.
od: McLaren, J, i dr.
Izdano: (2002)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
od: Luqmani, R, i dr.
Izdano: (1999)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
od: Luqmani, R
Izdano: (2013)